Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Risk factors for venous thromboembolism in immunoglobulin light chain amyloidosis.

Bever KM, Masha LI, Sun F, Stern L, Havasi A, Berk JL, Sanchorawala V, Seldin DC, Sloan JM.

Haematologica. 2016 Jan;101(1):86-90. doi: 10.3324/haematol.2015.133900. Epub 2015 Oct 9.

2.

Retrospective analysis of a novel regimen for the prevention of venous thromboembolism in nephrotic syndrome.

Medjeral-Thomas N, Ziaj S, Condon M, Galliford J, Levy J, Cairns T, Griffith M.

Clin J Am Soc Nephrol. 2014 Mar;9(3):478-83. doi: 10.2215/CJN.07190713. Epub 2013 Dec 12.

3.

Association of serum albumin level and venous thromboembolic events in a large cohort of patients with nephrotic syndrome.

Gyamlani G, Molnar MZ, Lu JL, Sumida K, Kalantar-Zadeh K, Kovesdy CP.

Nephrol Dial Transplant. 2017 Jan 1;32(1):157-164. doi: 10.1093/ndt/gfw227.

4.

Association Between Decreased Serum Albumin With Risk of Venous Thromboembolism and Mortality in Cancer Patients.

Königsbrügge O, Posch F, Riedl J, Reitter EM, Zielinski C, Pabinger I, Ay C.

Oncologist. 2016 Feb;21(2):252-7. doi: 10.1634/theoncologist.2015-0284. Epub 2016 Jan 13.

5.

Venous thromboembolism in patients with membranous nephropathy.

Lionaki S, Derebail VK, Hogan SL, Barbour S, Lee T, Hladunewich M, Greenwald A, Hu Y, Jennette CE, Jennette JC, Falk RJ, Cattran DC, Nachman PH, Reich HN.

Clin J Am Soc Nephrol. 2012 Jan;7(1):43-51. doi: 10.2215/CJN.04250511. Epub 2011 Nov 10.

6.

The incidence of and risk factors for venous thromboembolism (VTE) and bleeding among 1514 patients undergoing hematopoietic stem cell transplantation: implications for VTE prevention.

Gerber DE, Segal JB, Levy MY, Kane J, Jones RJ, Streiff MB.

Blood. 2008 Aug 1;112(3):504-10. doi: 10.1182/blood-2007-10-117051. Epub 2008 May 14.

7.

Venous thromboembolism in cancer patients.

Deng A, Galanis T, Graham MG.

Hosp Pract (1995). 2014 Dec;42(5):24-33. doi: 10.3810/hp.2014.12.1156. Review.

PMID:
25485915
8.

Inflammation markers and incident venous thromboembolism: the REasons for Geographic And Racial Differences in Stroke (REGARDS) cohort.

Olson NC, Cushman M, Lutsey PL, McClure LA, Judd S, Tracy RP, Folsom AR, Zakai NA.

J Thromb Haemost. 2014 Dec;12(12):1993-2001. doi: 10.1111/jth.12742. Epub 2014 Oct 31.

9.

Life-threatening hematuria in a hemodialysis patient with systemic light-chain amyloidosis.

Hsiao PJ, Chiang WF, Chao TK, Lin SH.

Clin Chim Acta. 2015 Dec 7;451(Pt B):180-2. doi: 10.1016/j.cca.2015.09.027. Epub 2015 Oct 21.

PMID:
26434538
10.

Recurrent venous thromboembolism in anticoagulated patients with cancer: management and short-term prognosis.

Schulman S, Zondag M, Linkins L, Pasca S, Cheung YW, de Sancho M, Gallus A, Lecumberri R, Molnar S, Ageno W, Le Gal G, Falanga A, Hulegårdh E, Ranta S, Kamphuisen P, Debourdeau P, Rigamonti V, Ortel TL, Lee A.

J Thromb Haemost. 2015 Jun;13(6):1010-8. doi: 10.1111/jth.12955. Epub 2015 May 9.

11.

Personalized prophylactic anticoagulation decision analysis in patients with membranous nephropathy.

Lee T, Biddle AK, Lionaki S, Derebail VK, Barbour SJ, Tannous S, Hladunewich MA, Hu Y, Poulton CJ, Mahoney SL, Charles Jennette J, Hogan SL, Falk RJ, Cattran DC, Reich HN, Nachman PH.

Kidney Int. 2014 Jun;85(6):1412-20. doi: 10.1038/ki.2013.476. Epub 2013 Dec 11.

12.

Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis.

Kourelis TV, Kumar SK, Gertz MA, Lacy MQ, Buadi FK, Hayman SR, Zeldenrust S, Leung N, Kyle RA, Russell S, Dingli D, Lust JA, Lin Y, Kapoor P, Rajkumar SV, McCurdy A, Dispenzieri A.

J Clin Oncol. 2013 Dec 1;31(34):4319-24. doi: 10.1200/JCO.2013.50.8499. Epub 2013 Oct 21.

13.

Increased serum free light chains precede the presentation of immunoglobulin light chain amyloidosis.

Weiss BM, Hebreo J, Cordaro DV, Roschewski MJ, Baker TP, Abbott KC, Olson SW.

J Clin Oncol. 2014 Sep 1;32(25):2699-704. doi: 10.1200/JCO.2013.50.0892. Epub 2014 Jul 14.

14.

Chemical venous thromboembolic prophylaxis is safe and effective for patients with traumatic brain injury when started 24 hours after the absence of hemorrhage progression on head CT.

Saadeh Y, Gohil K, Bill C, Smith C, Morrison C, Mosher B, Schneider P, Stevens P, Kepros JP.

J Trauma Acute Care Surg. 2012 Aug;73(2):426-30. doi: 10.1097/TA.0b013e31825a758b.

PMID:
22846950
15.

Cancer effect on periprocedural thromboembolism and bleeding in anticoagulated patients.

Tafur AJ, Wysokinski WE, McBane RD, Wolny E, Sutkowska E, Litin SC, Daniels PR, Slusser JP, Hodge DO, Heit JA.

Ann Oncol. 2012 Aug;23(8):1998-2005. doi: 10.1093/annonc/mds058. Epub 2012 Apr 3.

PMID:
22473596
16.

Serum albumin and risk of venous thromboembolism.

Folsom AR, Lutsey PL, Heckbert SR, Cushman M.

Thromb Haemost. 2010 Jul;104(1):100-4. doi: 10.1160/TH09-12-0856. Epub 2010 Apr 13.

17.

Risks and cost burden of venous thromboembolism and bleeding for patients undergoing total hip or knee replacement in a managed-care population.

Vekeman F, LaMori JC, Laliberté F, Nutescu E, Duh MS, Bookhart BK, Schein J, Dea K, Olson WH, Lefebvre P.

J Med Econ. 2011;14(3):324-34. doi: 10.3111/13696998.2011.578698. Epub 2011 Apr 20.

PMID:
21506632
18.

Clinical significance of the neutrophil-lymphocyte ratio in venous thromboembolism patients with lung cancer.

Go SI, Lee A, Lee US, Choi HJ, Kang MH, Kang JH, Jeon KN, Park MJ, Kim SH, Lee GW.

Lung Cancer. 2014 Apr;84(1):79-85. doi: 10.1016/j.lungcan.2014.01.014. Epub 2014 Jan 28.

PMID:
24524817
19.

Natural history of thromboembolism in AL amyloidosis.

Halligan CS, Lacy MQ, Vincent Rajkumar S, Dispenzieri A, Witzig TE, Lust JA, Fonseca R, Gertz MA, Kyle RA, Pruthi RK.

Amyloid. 2006 Mar;13(1):31-6.

PMID:
16690498
20.

Venous thromboprophylaxis in gastrointestinal bleeding.

Malhotra N, Chande N.

Can J Gastroenterol Hepatol. 2015 Apr;29(3):145-8.

Supplemental Content

Support Center